<DOC>
	<DOCNO>NCT01653743</DOCNO>
	<brief_summary>This open-label , parallel-group , randomize , multicenter Phase III trial compare efficacy safety single 250 microgram ( mcg ) subcutaneous dose MSJ-0011 single 5,000 international unit ( IU ) intramuscular dose urinary human chorionic gonadotropin ( hCG ) induce ovulation Japanese woman diagnose anovulation oligo-ovulation . Ovulation induction therapy undertaken follitropin alfa . The primary objective show MSJ-0011 non-inferior urinary hCG , assess ovulation rate .</brief_summary>
	<brief_title>Trial Assess Clinical Efficacy Safety MSJ-0011 Inducing Ovulation Anovulatory Oligo-ovulatory Japanese Women</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Pituitary Diseases</mesh_term>
	<mesh_term>Polycystic Ovary Syndrome</mesh_term>
	<mesh_term>Anovulation</mesh_term>
	<mesh_term>Chorionic Gonadotropin</mesh_term>
	<mesh_term>Follicle Stimulating Hormone</mesh_term>
	<criteria>Premenopausal woman age 20 39 year inclusive wish conceive Body Mass Index ( BMI ) 17.0 29.0 kilogram per square meter ( kg/m^2 ) inclusive ( value first decimal place ) No clinically significant abnormality serum thyroid stimulate hormone ( TSH ) , dehydroepiandrosterone sulfate ( DHEAS ) , 17hydroxyProgesterone ( 17OHP ) , prolactin ( PRL ) folliclestimulating hormone ( FSH ) level early follicular phase Anovulation oligoovulation Any one following : spontaneous menstruation ( least twice per year ) positive response progestin evidence menstruation . Eligible ovarian stimulation gonadotropin ( e.g . documented failure ovulate achieve pregnancy antiestrogenic therapy clomiphene citrate ) Male partner normal semen analysis , define World Health Organization ( WHO ) standard , within 12 month prior date informed consent Normal cervical smear result ( Papanicolaou [ PAP ] score less equal [ &lt; = ] II ) take within 12 month prior date informed consent ; available cervical smear perform part screen Full comprehension trial voluntary consent obtain write prior participation trial Infertility involve gynecological factor anovulation oligoovulation secondary hypothalamicpituitary dysfunction ( Grade 1 Amenorrhea , Oligomenorrhea Anovulatory Cycles ) polycystic ovarian syndrome ( PCOS ) ovulation induction ( OI ) therapy contraindicated Subjects know surgical/histological diagnosis endometriosis great Stage II ( American Fertility Society classification ) , endometriosis require treatment Infertility secondary amenorrhea uterine cause Infertility secondary primary premature ovarian failure Infertility secondary know adrenal thyroid dysfunction , hyperprolactinemia Failure ovulation 2 consecutive previous cycle gonadotropin Subjects pregnancy contraindicate , e.g . malformation sexual organ fibroid tumor uterus incompatible pregnancy Extrauterine pregnancy previous 3 month History presence intracranial tumor ( e.g . hypothalamic pituitary tumor ) Presence suspect gonadotropin estrogendependent malignancy ( e.g . ovarian , uterine mammary carcinoma ) Untreated endometrial hyperplasia Abnormal hemorrhage reproductive tract unknown origin History severe ovarian hyper stimulation syndrome ( OHSS ) ( Classification OHSS Severity , Japan Reproductive/Endocrine Working Group ) Clinically significant systemic disease ( e.g . insulindependent diabetes , epilepsy , severe migraine , intermittent porphyria , hepatic , renal cardiovascular disease , severe corticosteroiddependent asthma ) Participation another clinical trial within 3 month prior date informed consent simultaneous participation another clinical trial Gonadotropin treatment within 2 month prior date informed consent Legal incapacity limit legal capacity</criteria>
	<gender>Female</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>39 Years</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>Japanese</keyword>
</DOC>